Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cytel

This article was originally published in The Tan Sheet

Executive Summary

Cytel: Reaches milestone in Abbott project to develop manufacturing processes to provide carbohydrates for use in Abbott nutritional products, triggering a $1.5 mil. payment to San Diego-based Cytel. With achievement of the milestone, the technology is being transferred to Abbott for use by its Ross Products division. Cytel's proprietary technology, for enzymatic sugar nucleotide cycling is dubbed SNC Technology. SNC makes large-scale, economic production of bioactive carbohydrates commercially viable, Cytel says. The company is pursuing other collaborations for therapeutic medical and consumer products through its new Glycotechnology business unit. In addition to Abbott, Cytel established a collaboration with the Nextran unit of Baxter last year..
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel